Journal of glaucoma · 2001
Dorzolamide-induced immune thrombocytopenia: a case report and literature review.
Клинический случайСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Martin X D, Danese M
Аннотация
PURPOSE: To report a severe case of dorzolamide-induced immune thrombocytopenia, to review the literature on this topic, and to draw attention to the serious potential side effects of this topical sulfonamide.
CASE REPORT: An 83-year-old man with primary open-angle glaucoma in both eyes who was taking topical dorzolamide therapy for 3.5 years developed a severe thrombocytopenia (10,000 platelets/microL). The amount of platelets was not influenced by prednisone therapy but increased rapidly to 100,000/microL after the withdrawal of dorzolamide.
LITERATURE REVIEW: Although the potential capacity of sulfonamides to induce thrombocytopenia is well known, no case of dorzolamide-induced immune thrombocytopenia was published in the medical literature until July 2000.
CONCLUSION: Considering the possible severe side effects that can be induced by topical dorzolamide 2%, ophthalmologists should carefully evaluate during the medical history of their patients the risk of sensitivity to sulfonamides.
CASE REPORT: An 83-year-old man with primary open-angle glaucoma in both eyes who was taking topical dorzolamide therapy for 3.5 years developed a severe thrombocytopenia (10,000 platelets/microL). The amount of platelets was not influenced by prednisone therapy but increased rapidly to 100,000/microL after the withdrawal of dorzolamide.
LITERATURE REVIEW: Although the potential capacity of sulfonamides to induce thrombocytopenia is well known, no case of dorzolamide-induced immune thrombocytopenia was published in the medical literature until July 2000.
CONCLUSION: Considering the possible severe side effects that can be induced by topical dorzolamide 2%, ophthalmologists should carefully evaluate during the medical history of their patients the risk of sensitivity to sulfonamides.